RecruitingPhase 3NCT05261139

EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease

Studying Periodontal Ehlers-Danlos syndrome

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Pfizer
Principal Investigator
Pfizer CT.gov Call Center
Pfizer
Intervention
nirmatrelvir(drug)
Enrollment
160 enrolled
Eligibility
0-17 years · All sexes
Timeline
20222026

Study locations (30)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05261139 on ClinicalTrials.gov

Other trials for Periodontal Ehlers-Danlos syndrome

Additional recruiting or active studies for the same condition.

See all trials for Periodontal Ehlers-Danlos syndrome

← Back to all trials